Does TARLATAMAB-DLLE Cause Decreased appetite? 23 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Decreased appetite have been filed in association with TARLATAMAB-DLLE (IMDELLTRA (AMG757)). This represents 2.9% of all adverse event reports for TARLATAMAB-DLLE.
23
Reports of Decreased appetite with TARLATAMAB-DLLE
2.9%
of all TARLATAMAB-DLLE reports
1
Deaths
8
Hospitalizations
How Dangerous Is Decreased appetite From TARLATAMAB-DLLE?
Of the 23 reports, 1 (4.3%) resulted in death, 8 (34.8%) required hospitalization, and 1 (4.3%) were considered life-threatening.
Is Decreased appetite Listed in the Official Label?
Yes, Decreased appetite is listed as a known adverse reaction in the official FDA drug label for TARLATAMAB-DLLE.
What Other Side Effects Does TARLATAMAB-DLLE Cause?
Cytokine release syndrome (274)
Immune effector cell-associated neurotoxicity syndrome (127)
Off label use (111)
Pyrexia (75)
Small cell lung cancer (66)
Death (45)
Disease progression (34)
Metastases to central nervous system (28)
Dysgeusia (22)
Fatigue (22)
What Other Drugs Cause Decreased appetite?
ADALIMUMAB (6,135)
LENALIDOMIDE (5,103)
SEMAGLUTIDE (4,317)
METHOTREXATE (4,229)
CABOZANTINIB S-MALATE (4,076)
APREMILAST (3,442)
RITUXIMAB (3,438)
PALBOCICLIB (3,400)
PREDNISONE (3,390)
LENVATINIB (3,257)
Which TARLATAMAB-DLLE Alternatives Have Lower Decreased appetite Risk?
TARLATAMAB-DLLE vs TASIGNA
TARLATAMAB-DLLE vs TASIMELTEON
TARLATAMAB-DLLE vs TAVABOROLE
TARLATAMAB-DLLE vs TAXOL
TARLATAMAB-DLLE vs TAXOTERE